Nia Impact Advisors LLC Takes $1.48 Million Position in GeneDx Holdings Corp. (NASDAQ:WGS)

Nia Impact Advisors LLC purchased a new stake in GeneDx Holdings Corp. (NASDAQ:WGS) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 19,256 shares of the company’s stock, valued at approximately $1,480,000.

A number of other large investors also recently modified their holdings of WGS. MCF Advisors LLC increased its holdings in GeneDx by 107.7% in the fourth quarter. MCF Advisors LLC now owns 351 shares of the company’s stock valued at $27,000 after purchasing an additional 182 shares during the period. Sterling Capital Management LLC increased its holdings in GeneDx by 877.8% in the fourth quarter. Sterling Capital Management LLC now owns 352 shares of the company’s stock valued at $27,000 after purchasing an additional 316 shares during the period. Global Retirement Partners LLC acquired a new stake in GeneDx during the 4th quarter worth about $28,000. Lazard Asset Management LLC acquired a new stake in GeneDx during the 4th quarter worth about $35,000. Finally, Comerica Bank acquired a new stake in GeneDx during the 4th quarter worth about $50,000. 61.72% of the stock is currently owned by institutional investors.

Insider Activity at GeneDx

In related news, CEO Katherine Stueland sold 2,731 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $94.73, for a total value of $258,707.63. Following the transaction, the chief executive officer now owns 7,752 shares of the company’s stock, valued at approximately $734,346.96. This trade represents a 26.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Kevin Feeley sold 402 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $90.05, for a total transaction of $36,200.10. Following the completion of the transaction, the chief financial officer now directly owns 5,044 shares in the company, valued at approximately $454,212.20. The trade was a 7.38% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 139,390 shares of company stock valued at $13,043,288. 27.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on WGS. TD Securities decreased their price target on GeneDx from $135.00 to $110.00 and set a “buy” rating for the company in a report on Thursday, May 1st. The Goldman Sachs Group increased their price objective on shares of GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 19th. Wells Fargo & Company cut their price objective on shares of GeneDx from $105.00 to $78.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 1st. Finally, Jefferies Financial Group raised shares of GeneDx from a “hold” rating to a “buy” rating and set a $80.00 price objective on the stock in a research report on Friday, May 9th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.57.

GeneDx Price Performance

Shares of NASDAQ WGS opened at $60.93 on Wednesday. GeneDx Holdings Corp. has a fifty-two week low of $19.16 and a fifty-two week high of $117.75. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -31.09 and a beta of 1.96. The company has a debt-to-equity ratio of 0.25, a quick ratio of 2.27 and a current ratio of 2.40. The firm’s 50-day simple moving average is $88.77 and its 200 day simple moving average is $82.83.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.17. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The business had revenue of $87.12 million for the quarter, compared to analysts’ expectations of $79.90 million. As a group, research analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

GeneDx Company Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.